Responses cited increasing workloads, shrinking autonomy, mounting interference from hospital administrators and insurance ...

ICE raids are disrupting worksites across the country, particularly construction sites, as President Trump’s mass deportation ...

Calling the Iranian regime "evil," Belgium's prime minister reluctantly endorsed the notion of a regime change in Tehran on ...

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...

The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...

Justin Tucker, one of the best kickers in NFL history, suspended for 10 weeks after 16 women said he was sexually ...

In “Sick and Dirty,” author Michael Koresky takes a clear-eyed look at golden age Hollywood’s stealth queerness on screen.

Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.

Pfizer said on Thursday its hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain ...

Pfizer announces positive results from phase 3 BASIS study of Hympavzi in haemophilia A or B with inhibitors: New York Friday, June 27, 2025, 10:00 Hrs [IST] Pfizer Inc. announced ...